BI 770371
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 9, 2022 (NCT05327946)
Timeline
Indications
Mechanism of action
- Pigment epithelium-derived factorINHIBITOR
SERPINF1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06806852 | Phase 1 | May 1, 2025 | Boehringer Ingelheim |
| NCT06675929 | Phase 2 | Nov 25, 2024 | Boehringer Ingelheim |
| NCT05327946 | Phase 1 | May 9, 2022 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 3 | 3 | 2 | 2022 |
1 organizations
Page 1 / 1